Export 53 results:
Autore Titolo Tipo [ Anno(Desc)]
Filtri: Autore è Secchiero, Paola  [Clear All Filters]
2012
Tisato V, Monasta L, Biolo G, Donatelli F, Secchiero P, Zauli G. Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: potential role of C-reactive protein. Cytokine 2012;60(3):593-5.
Agostinis C, Bulla R, Tisato V, De Seta F, Alberico S, Secchiero P, Zauli G. Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Hum Reprod 2012;27(10):2941-7.
Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MGrazia, Lanza F, Secchiero P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.
Bernardi S, Secchiero P, Zauli G. State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7(2):207-17.
Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P, Cooper ME, Thomas MC. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.
Secchiero P, Zauli G. TRAIL, a new weapon against neointimal hyperplasia. Cardiology 2012;123(2):94-6.
Marcuzzi A, Secchiero P, Crovella S, Zauli G. TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine 2012;60(1):43-6.
Bernardi S, Milani D, Fabris B, Secchiero P, Zauli G. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.
Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.

Amministrazione Trasparente